HK1257189A1 - 用於抑制癌症幹細胞的組合物和方法 - Google Patents

用於抑制癌症幹細胞的組合物和方法

Info

Publication number
HK1257189A1
HK1257189A1 HK18116166.4A HK18116166A HK1257189A1 HK 1257189 A1 HK1257189 A1 HK 1257189A1 HK 18116166 A HK18116166 A HK 18116166A HK 1257189 A1 HK1257189 A1 HK 1257189A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
stem cells
cancer stem
inhibiting cancer
Prior art date
Application number
HK18116166.4A
Other languages
English (en)
Inventor
Elaine M Hurt
Ralph Minter
Steven Rust
Alan Sandercock
Sotirios Karathanasis
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1257189A1 publication Critical patent/HK1257189A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
HK18116166.4A 2015-09-30 2018-12-18 用於抑制癌症幹細胞的組合物和方法 HK1257189A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235144P 2015-09-30 2015-09-30
PCT/EP2016/073362 WO2017055511A1 (en) 2015-09-30 2016-09-29 Compositions and methods for inhibiting cancer stem cells

Publications (1)

Publication Number Publication Date
HK1257189A1 true HK1257189A1 (zh) 2019-10-18

Family

ID=57121217

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18114177.6A HK1255053A1 (zh) 2015-09-30 2018-11-07 用於抑制癌症幹細胞的組合物和方法
HK18116166.4A HK1257189A1 (zh) 2015-09-30 2018-12-18 用於抑制癌症幹細胞的組合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18114177.6A HK1255053A1 (zh) 2015-09-30 2018-11-07 用於抑制癌症幹細胞的組合物和方法

Country Status (13)

Country Link
US (2) US11192948B2 (zh)
EP (1) EP3356414A1 (zh)
JP (1) JP6938478B2 (zh)
KR (1) KR20180054818A (zh)
CN (1) CN108290952B (zh)
AU (2) AU2016329409B2 (zh)
CA (1) CA3000285A1 (zh)
HK (2) HK1255053A1 (zh)
IL (1) IL258242B2 (zh)
MA (1) MA43342A (zh)
RU (2) RU2752610C1 (zh)
SG (1) SG10202002926UA (zh)
WO (1) WO2017055511A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120474A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1572915A4 (en) 2002-04-11 2011-01-05 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
JP2006022063A (ja) 2004-07-09 2006-01-26 Univ Nihon Ｌｏｘ−１遺伝子発現抑制剤
WO2008103953A2 (en) 2007-02-23 2008-08-28 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
US20090311271A1 (en) 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
US8628959B2 (en) 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
US9778264B2 (en) * 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2678682A4 (en) 2011-02-24 2014-10-01 Vermillion Inc BIOLOGICAL MARKERS PANEL, DIAGNOSTIC METHODS AND TESTING NEEDS FOR OVARIAN CANCER
KR20150041149A (ko) 2012-08-15 2015-04-15 네오스템 온콜로지, 엘엘씨 고순도 암 줄기 세포 및 고순도 암 줄기 세포 개체군의 신속한 생성 방법
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
KR102571909B1 (ko) 2014-10-01 2023-08-28 메디뮨 리미티드 Lox1에 특이적인 결합 단백질 및 이의 용도

Also Published As

Publication number Publication date
MA43342A (fr) 2018-08-08
RU2752610C1 (ru) 2021-07-29
US11192948B2 (en) 2021-12-07
IL258242B (en) 2022-10-01
US20180273616A1 (en) 2018-09-27
SG10202002926UA (en) 2020-05-28
CA3000285A1 (en) 2017-04-06
AU2020201276B2 (en) 2022-03-17
IL258242B2 (en) 2023-02-01
RU2021120719A (ru) 2021-11-03
WO2017055511A1 (en) 2017-04-06
EP3356414A1 (en) 2018-08-08
US20220195037A1 (en) 2022-06-23
IL258242A (en) 2018-05-31
AU2016329409A1 (en) 2018-05-10
KR20180054818A (ko) 2018-05-24
HK1255053A1 (zh) 2019-08-02
CN108290952B (zh) 2023-05-02
AU2020201276A1 (en) 2020-03-12
AU2016329409B2 (en) 2019-11-28
JP2018529716A (ja) 2018-10-11
CN108290952A (zh) 2018-07-17
JP6938478B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
IL304820A (en) Preparations and methods for the treatment of cancer
HK1251610A1 (zh) 用於抑制因子d的組合物和方法
PT3377516T (pt) Composição para o tratamento do cancro
GB201513304D0 (en) Compositions and Methods
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL256523A (en) Compositions and methods for treating cancer
HK1258528A1 (zh) 幹細胞移植方法和幹細胞移植組合物
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
EP3213752A4 (en) Composition for treating cancer stem cells
SG11201701237QA (en) Compositions for modulating cancer stem cells and uses therefor
RS62981B1 (sr) Kompozicije i postupci za stimulaciju matičnih ćelija
EP3286179A4 (en) Compositions and methods for inhibiting kinases
GB201613078D0 (en) Stem cells and cancer
IL255638A (en) Compositions and methods for treating cancer
HK1257189A1 (zh) 用於抑制癌症幹細胞的組合物和方法
GB201512996D0 (en) Compositions and methods
HK1250958A1 (zh) 用於治療癌症的組合物和方法
GB201514413D0 (en) Compositions and methods
GB201514415D0 (en) Compositions and methods